Table 2.
Patient Characteristics-Surveillance Cohort
| Factor | Total (N=1011) | NHW (N=991) | African-American (N=20) | p-value | ||
|---|---|---|---|---|---|---|
| n | Summary | n | Summary | |||
| Age at BE Diagnosis (Years) | 58.0±12.7 | 991 | 57.9±12.7 | 20 | 61.3±12.0 | 0.24a |
| Male (%) | 724(71.6) | 991 | 716(72.3) | 20 | 8(40.0) | 0.002 |
| BMI (All ) | 29.7±5.9 | 510 | 29.6±5.8 | 16 | 30.4±6.3 | 0.62a |
| BMI (Male) | 29.5±5.4 | 365 | 29.5±5.4 | 6 | 29.7±5.7 | 0.92a |
| BMI (Female) | 29.9±6.8 | 145 | 29.8±6.8 | 10 | 30.7±6.9 | 0.70a |
| BE Length (cm) | 3.0±3.4 | 991 | 3.0±3.4 | 20 | 2.9±2.8 | 0.88a |
| Hiatal Hernia (cm) | 2.2±3.1 | 991 | 2.2±3.1 | 20 | 3.0±2.8 | 0.26a |
| Aspirin | 260(27.1) | 938 | 257(27.4) | 20 | 3(15.0) | 0.22c |
| NSAIDs | 385(40.2) | 938 | 380(40.5) | 20 | 5(25.0) | 0.16c |
| PPI | 463(48.3) | 938 | 457(48.7) | 20 | 6(30.0) | 0.097 |
| H2 RA | 278(29.0) | 938 | 273(29.1) | 20 | 5(25.0) | 0.69c |
| Baseline Histology | 991 | 20 | 0.84c | |||
| . No dysplasia | 843(83.4) | 826(83.4) | 17(85.0) | |||
| . LGD | 168(16.6) | 165(16.6) | 3(15.0) | |||
| Progression to HGD/EAC | 55(5.4) | 991 | 54(5.4) | 20 | 1(5.0) | 0.93c |
| Any Progression | 191(18.9) | 991 | 188(19.0) | 20 | 3(15.0) | 0.65c |
| Follow -up (months) | 43.0[20.6,81.2] | 991 | 43.1[20.5,81.6] | 20 | 36.9[29.4,49.7] | 0.65b |
Values presented as Mean ± SD, Median [P25, P75] or N (column %).
p-values:
a
=ANOVA,
b
=Kruskal-Wallis test,
c
=Pearson’s chi-square test,
d
=Fisher’s Exact test.
BE= Barrett’s Esophagus; BMI= Body Mass Index; EAC= Esophageal Adenocarcinoma; HGD= High-Grade Dysplasia; histamine receptor antagonists= H2RA; LGD= Low-Grade Dysplasia; NHW= Non-hispanic whites; nonsteroidal anti-inflammatory drugs = NSAID; proton pump inhibitors = PPI